Just in case you all still think they are on the right track with these methods of treating mood disorders, look at the data you are basing your claims on.
"Meta-analyses by industry employees were 22 times less likely to have negative statements about a drug than those run by unaffiliated researchers. The rate of bias in the results is similar to a 2006 study examining industry impact on clinical trials of psychiatric medications, which found that industry-sponsored trials reported favorable outcomes 78 per cent of the time, compared with 48 percent in independently funded trials."
And if you think MDMA treatment is not about money you are worse than ignorant:
Venture capital firms have taken notice—pouring money into startups developing psychedelic treatments for everything from PTSD to smoking cessation. A January analysis by Business Insider identified 11 venture capital firms (most of them founded in the past three years) that have collectively invested roughly $140 million in the psychedelics category. Funding accelerated after psychedelic startup Compass Pathways raised $146 million in its September 2020 initial public offering and an additional $144 million in a secondary offering in April 2021.
https://www.scientificamerican.com/article/many-antidepressa...
"Meta-analyses by industry employees were 22 times less likely to have negative statements about a drug than those run by unaffiliated researchers. The rate of bias in the results is similar to a 2006 study examining industry impact on clinical trials of psychiatric medications, which found that industry-sponsored trials reported favorable outcomes 78 per cent of the time, compared with 48 percent in independently funded trials."
And if you think MDMA treatment is not about money you are worse than ignorant:
https://www.fastcompany.com/90720911/mindstate-psychedelics
Venture capital firms have taken notice—pouring money into startups developing psychedelic treatments for everything from PTSD to smoking cessation. A January analysis by Business Insider identified 11 venture capital firms (most of them founded in the past three years) that have collectively invested roughly $140 million in the psychedelics category. Funding accelerated after psychedelic startup Compass Pathways raised $146 million in its September 2020 initial public offering and an additional $144 million in a secondary offering in April 2021.